Biopsy versus resection decision

What it is

The biopsy-versus-resection decision is the choice between obtaining tissue alone (biopsy) and removing the tumor (resection). It depends on whether the glioma can be safely and beneficially removed and on the goals of treatment, and it is made together with the surgical and oncology team.

Understanding Biopsy versus resection decision

When a glioma is diagnosed, an early decision is how surgery will be used. If the tumor is in a location where it can be safely removed and removal would benefit the person (relieving symptoms and, for many tumors, improving outcomes), resection is generally favored — accomplishing both diagnosis and treatment. If the tumor cannot be safely removed — because of its location (such as the brainstem or deep midline), its widespread nature, or involvement of critical areas — then biopsy alone is chosen to establish the diagnosis (including molecular features) so that non-surgical treatment can proceed. The decision weighs the potential benefit of removal against the risks, considering the tumor's location, type, and the person's condition and goals. It is a key early decision that shapes the treatment plan and is made collaboratively. Understanding the biopsy-versus-resection decision clarifies how the role of surgery is chosen for each person.

Why it matters

Understanding the biopsy-versus-resection decision helps patients and families see how the team decides whether to remove a glioma or sample it — based on whether removal is safe and beneficial — shaping the treatment plan.